Showing results (241-250 of 277) with videos related to
Sort By:
Pageof 28
Biorxiv : the Preprint Server for Biology|August 30, 2023
EZH2 synergizes with BRD4-NUT to drive NUT carcinoma growth through silencing of key tumor suppressor genesYeying Huang, R Taylor Durall, Nhi M Luong, et al.Nature Cancer|March 19, 2021
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancerAnita K Mehta, Emily M Cheney, Christina A Hartl, et al.Cancer Discovery|October 1, 2013
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumorsEsra A Akbay, Shohei Koyama, Julian Carretero, et al.Nature Communications|February 6, 2023
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancersJames J Harding, Sarina A Piha-Paul, Ronak H Shah, et al.The Lancet. Oncology|March 19, 2019
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trialPanagiotis A Konstantinopoulos, William T Barry, Michael Birrer, et al.Cancer Cell|June 15, 2010
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumorsJulian Carretero, Takeshi Shimamura, Klarisa Rikova, et al.Cancer Discovery|December 17, 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J Sullivan, Jeffrey R Infante, Filip Janku, et al.Cancer Research|September 25, 2023
EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor GenesYeying Huang, R Taylor Durall, Nhi M Luong, et al.Nature Medicine|May 26, 2026
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trialPriscilla Merriam, James J Morrow, Emanuele Mazzola, et al.Cancer Discovery|January 30, 2013
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvementJosep Tabernero, Geoffrey I Shapiro, Patricia M LoRusso, et al.Pageof 28